Nike Gains 434% Q3 Stake Boost and Posts $0.53 EPS

NKENKE

Mediolanum raised its Nike stake by 434% to 307,370 shares worth $21.4M in Q3, while Truist and Audent cut holdings by 5.4% and 62.5%, respectively. Nike beat Q2 estimates with $0.53 EPS vs. $0.37 and raised its quarterly dividend to $0.41 (2.7% yield), as insiders acquired over 91,000 shares.

1. Major Stake Increase by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd expanded its position in Nike by 434.4% during the third quarter, purchasing an additional 249,851 shares to bring its total holding to 307,370 shares. At quarter’s end, the fund’s investment in the footwear and apparel leader was valued at approximately $21.4 million. This outsized accumulation outpaced most of its peers and highlights growing confidence among certain institutional investors in the company’s long-term growth trajectory.

2. Quarterly Earnings Beat and Dividend Hike

In its most recent quarterly report, Nike delivered diluted earnings per share of $0.53, surpassing consensus estimates by $0.16, on revenues of $12.43 billion—0.6% above the year-ago period. Return on equity reached 18.4% and net margin stood at 5.4%. Shortly after, the board raised the quarterly cash dividend by $0.01 to $0.41 per share, reflecting a 2.7% annualized yield and a payout ratio near 96.5%.

3. Significant Insider Accumulation

During the fourth quarter, two senior executives increased their holdings substantially. Director Timothy D. Cook acquired 50,000 shares at an average cost of $58.97 per share, boosting his stake by 90.1% to 105,480 shares. CEO Elliott Hill purchased 16,388 shares at an average of $61.10, lifting his ownership by 7.3% to 241,587 shares. Insiders in total amassed 91,229 shares valued at $5.45 million, underscoring executive alignment with shareholder interests.

4. Analyst Rating Revisions and Consensus Outlook

Several brokerages adjusted their price targets and ratings following the quarter’s results. Argus lowered its target from $85 to $70, KeyCorp reduced it from $90 to $75 while maintaining an overweight stance, and JPMorgan trimmed its view from $100 to $86 with a buy recommendation. Overall, among 37 analysts covering the stock, two have Strong Buy, 22 have Buy, 12 Hold and one Sell, yielding a consensus Moderate Buy rating and an average target near $74.6.

Sources

DDD